Kala Pharmaceuticals Inc (KALA) | Stock Price, Analysis, News, Fundaments & Technical Information

stock

Kala Pharmaceuticals Inc

NASDAQ | KALA

4.61

USD

-0.16 (-3.35%)

AT CLOSE (AS OF Apr 3, 2025)

$29M

MARKET CAP

P/E Ratio

-10.15

EPS

$11

52 Week High

$4.2

52 Week Low

LIFE SCIENCES

Sector

KALA Chart

Area

Trade Smarter

Take control of your trading journey with a set of smart tools for serious trades

Backtests

Strategy Backtester designed to automate your backtesting and revolutionize the way you trade

Learn More About Backtests

Scanner

Leverage the power of AI to detect valuable opportunities and gain the most out of the markets.

Learn More About Scanner

Signals

Automate your trading workflow with AI-powered trading signals to execute trades automatically.

Learn More About Signals

Journal

Record your trades and performance to improve your trading with AfterPullback’s Trading Journal

Learn More About Journal

KALA Technicals

Tags:

KALA Earnings

Yearly Income Statement (As of Dec 31, 2023)

Field	Value (USD)
Gross Profit	-$26M
Total Revenue	-
Cost Of Revenue	$21M
Costof Goods And Services Sold	$303K
Operating Income	-$40M
Selling General And Administrative	$21M
Research And Development	$19M
Operating Expenses	$40M
Investment Income Net	$2.7M
Net Interest Income	-$5.8M
Interest Income	$2.5M
Interest Expense	$5.8M
Non Interest Income	$0
Other Non Operating Income	-$4.3M
Depreciation	$248K
Depreciation And Amortization	$303K
Income Before Tax	-$42M
Income Tax Expense	$0
Interest And Debt Expense	$5.8M
Net Income From Continuing Operations	-$42M
Comprehensive Income Net Of Tax	-$42M
Ebit	-$36M
Ebitda	-$36M
Net Income	-$42M

Revenue & Profitability

Earnings Performance

KALA Financials

Highlights

Balance Sheet

Cash Flow

Income Statement

Yearly

Quarterly

yearly Balance Sheet (As of Dec 31, 2023)

Field	Value (USD)
Total Assets	$56M
Total Current Assets	$53M
Cash And Cash Equivalents At Carrying Value	$51M
Cash And Short Term Investments	$51M
Inventory	-
Current Net Receivables	$236K
Total Non Current Assets	$2.8M
Property Plant Equipment	$753K
Accumulated Depreciation Amortization Ppe	$1.1M
Intangible Assets	-
Intangible Assets Excluding Goodwill	-
Goodwill	-
Investments	-
Long Term Investments	-
Short Term Investments	-
Other Current Assets	$1.7M
Other Non Current Assets	-
Total Liabilities	$48M
Total Current Liabilities	$8.3M
Current Accounts Payable	$919K
Deferred Revenue	$1.1M
Current Debt	-
Short Term Debt	$334K
Total Non Current Liabilities	$40M
Capital Lease Obligations	$2.1M
Long Term Debt	$34M
Current Long Term Debt	-
Long Term Debt Noncurrent	$34M
Short Long Term Debt Total	$34M
Other Current Liabilities	$6M
Other Non Current Liabilities	$4.1M
Total Shareholder Equity	$7.5M
Treasury Stock	-
Retained Earnings	-$629M
Common Stock	$3K
Common Stock Shares Outstanding	$2.8M

yearly Cash Flow (As of Dec 31, 2023)

Field	Value (USD)
Operating Cashflow	-$28M
Payments For Operating Activities	$4.8M
Proceeds From Operating Activities	-
Change In Operating Liabilities	-$4.3M
Change In Operating Assets	-$13M
Depreciation Depletion And Amortization	$303K
Capital Expenditures	$610K
Change In Receivables	-$78K
Change In Inventory	-$7.5M
Profit Loss	-$42M
Cashflow From Investment	-$429K
Cashflow From Financing	$8.5M
Proceeds From Repayments Of Short Term Debt	-
Payments For Repurchase Of Common Stock	-
Payments For Repurchase Of Equity	-
Payments For Repurchase Of Preferred Stock	-
Dividend Payout	$365K
Dividend Payout Common Stock	$365K
Dividend Payout Preferred Stock	-
Proceeds From Issuance Of Common Stock	$19M
Proceeds From Issuance Of Long Term Debt And Capital Securities Net	-
Proceeds From Issuance Of Preferred Stock	$2M
Proceeds From Repurchase Of Equity	$21M
Proceeds From Sale Of Treasury Stock	-
Change In Cash And Cash Equivalents	-
Change In Exchange Rate	-
Net Income	-$42M

yearly Income Statement (As of Dec 31, 2023)

Field	Value (USD)
Gross Profit	-$26M
Total Revenue	-
Cost Of Revenue	$21M
Costof Goods And Services Sold	$303K
Operating Income	-$40M
Selling General And Administrative	$21M
Research And Development	$19M
Operating Expenses	$40M
Investment Income Net	$2.7M
Net Interest Income	-$5.8M
Interest Income	$2.5M
Interest Expense	$5.8M
Non Interest Income	$0
Other Non Operating Income	-$4.3M
Depreciation	$248K
Depreciation And Amortization	$303K
Income Before Tax	-$42M
Income Tax Expense	$0
Interest And Debt Expense	$5.8M
Net Income From Continuing Operations	-$42M
Comprehensive Income Net Of Tax	-$42M
Ebit	-$36M
Ebitda	-$36M
Net Income	-$42M

KALA Profile

Kala Pharmaceuticals Inc Profile

Sector: LIFE SCIENCES

Industry: PHARMACEUTICAL PREPARATIONS

Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development and commercialization of therapies using its proprietary nanoparticle-based mucus penetrating particle (MPP) technology for the treatment of eye diseases. The company is headquartered in Watertown, Massachusetts.

Most Active

Symbol	Price	Change %	Market Cap	Volume
DMN	$0.02	13.04%	-	706,860,781
NVDA	$103.14	-6.59%	$2.68T	263,349,217
LCID	$2.34	-2.30%	$7.67B	187,389,814
F	$9.68	-4.68%	$39.53B	173,285,336
PTIX	$0.43	91.50%	$4.04M	173,208,693

See more →

Symbol	Price	Change %	Market Cap	Volume
JNJ	$160.56	3.35%	$399.65B	9,908,361
PG	$172.76	1.92%	$399.61B	6,083,153
ABBV	$202.45	-1.34%	$364.89B	5,252,004
NVO	$67.60	-0.95%	$308.32B	7,033,051
AZN	$74.03	2.50%	$225.70B	6,150,517

See more →

Top Gainers

Symbol	Price	Change %	Market Cap	Volume
VCIG	$6.06	1,818.33%	$26.40M	302,396
MKTW	$9.19	1,684.81%	$19.91M	117,875
ICCT	$4.38	111.59%	$9.78M	168,784,937
PTIX	$0.43	91.50%	$4.04M	173,208,693
MRM	$0.65	74.84%	$2.91M	51,693,935

See more →

Top Losers

Symbol	Price	Change %	Market Cap	Volume
ALDX	$1.42	-73.33%	$326.91M	20,249,631
RFAC	$2.70	-68.60%	$8.44M	605,339
PKBO	$0.02	-67.86%	$531.87K	66,140
TCBP	$0.50	-67.53%	$360.37K	1,955,586
OMQS	$0.04	-66.36%	$1.50M	950,669